References analysis of the Wikipedia article "Fas ligand" in the English version

doi.org

Levoin N, Jean M, Legembre P (2020). "CD95 Structure, Aggregation and Cell Signaling". Frontiers in Cell and Developmental Biology. 8: 314. doi:10.3389/fcell.2020.00314. PMC 7214685. PMID 32432115.

Zhao L, Fu Q, Pan L, Piai A, Chou JJ (2020-10-14). "The Diversity and Similarity of Transmembrane Trimerization of TNF Receptors". Frontiers in Cell and Developmental Biology. 8: 569684. doi:10.3389/fcell.2020.569684. PMC 7591462. PMID 33163490.

Alderson MR, Lynch DH (January 1998). "FAS (CD95) and FAS Ligand". In Delves PJ (ed.). Encyclopedia of Immunology (Second ed.). Oxford: Elsevier. pp. 874–880. doi:10.1006/rwei.1999.0229. ISBN 978-0-12-226765-9. Retrieved 2025-04-16.

Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM (December 2002). "Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand". Archives of Biochemistry and Biophysics. 408 (2): 155–161. doi:10.1016/S0003-9861(02)00525-8. PMID 12464266.

Nareznoi D, Konikov-Rozenman J, Petukhov D, Breuer R, Wallach-Dayan SB (February 2020). "Matrix Metalloproteinases Retain Soluble FasL-mediated Resistance to Cell Death in Fibrotic-Lung Myofibroblasts". Cells. 9 (2): 411. doi:10.3390/cells9020411. PMC 7072292. PMID 32053892.

Kucka K, Wajant H (2021-02-11). "Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily". Frontiers in Cell and Developmental Biology. 8: 615141. doi:10.3389/fcell.2020.615141. PMC 7905041. PMID 33644033.

Guégan JP, Legembre P (March 2018). "Nonapoptotic functions of Fas/CD95 in the immune response". The FEBS Journal. 285 (5): 809–827. doi:10.1111/febs.14292. PMID 29032605.

Salvesen GS, Riedl SJ (September 2009). "Structure of the Fas/FADD complex: a conditional death domain complex mediating signaling by receptor clustering". Cell Cycle. 8 (17): 2723–2727. doi:10.4161/cc.8.17.9399. PMC 2788920. PMID 19652545.

Olsson M, Vakifahmetoglu H, Abruzzo PM, Högstrand K, Grandien A, Zhivotovsky B (May 2009). "DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis". Oncogene. 28 (18): 1949–1959. doi:10.1038/onc.2009.36. PMID 19347032.

Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N (2017-04-05). "Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance". Frontiers in Immunology. 8: 403. doi:10.3389/fimmu.2017.00403. PMC 5380675. PMID 28424702.

Bień K, Sokołowska J, Bąska P, Nowak Z, Stankiewicz W, Krzyzowska M (2015). "Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs". Mediators of Inflammation. 2015 (1): 281613. doi:10.1155/2015/281613. PMC 4385687. PMID 25873756.

Dockrell DH (August 2003). "The multiple roles of Fas ligand in the pathogenesis of infectious diseases". Clinical Microbiology and Infection. 9 (8): 766–779. doi:10.1046/j.1469-0691.2003.00669.x. PMID 14616696.

Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH, Lai MZ (September 1999). "NF-kappa B-dependent Fas ligand expression". European Journal of Immunology. 29 (9): 2948–2956. doi:10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0. PMID 10508269.

Wajant H, Pfizenmaier K, Scheurich P (February 2003). "Non-apoptotic Fas signaling". Cytokine & Growth Factor Reviews. 14 (1): 53–66. doi:10.1016/S1359-6101(02)00072-2. PMID 12485619.

Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (November 1995). "Fas ligand-induced apoptosis as a mechanism of immune privilege". Science. 270 (5239): 1189–1192. Bibcode:1995Sci...270.1189G. doi:10.1126/science.270.5239.1189. PMID 7502042.

Taylor AW (2016-02-08). "Ocular Immune Privilege and Transplantation". Frontiers in Immunology. 7: 37. doi:10.3389/fimmu.2016.00037. PMC 4744940. PMID 26904026.

Green DR, Ware CF (June 1997). "Fas-ligand: privilege and peril". Proceedings of the National Academy of Sciences of the United States of America. 94 (12): 5986–5990. Bibcode:1997PNAS...94.5986G. doi:10.1073/pnas.94.12.5986. PMC 33671. PMID 9177153.

Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S (October 1994). "Human Fas ligand: gene structure, chromosomal location and species specificity". International Immunology. 6 (10): 1567–1574. doi:10.1093/intimm/6.10.1567. PMID 7826947.

Liu W, Ramagopal U, Cheng H, Bonanno JB, Toro R, Bhosle R, et al. (November 2016). "Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3". Structure. 24 (11): 2016–2023. doi:10.1016/j.str.2016.09.009. PMID 27806260.

Sheikh MS, Fornace AJ (August 2000). "Death and decoy receptors and p53-mediated apoptosis". Leukemia. 14 (8): 1509–1513. doi:10.1038/sj.leu.2401865. PMID 10942251. S2CID 12572810.

Hsieh SL, Lin WW (June 2017). "Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions". Journal of Biomedical Science. 24 (1): 39. doi:10.1186/s12929-017-0347-7. PMC 5477258. PMID 28629361.

Leite-de-Moraes MC, Herbelin A, Gouarin C, Koezuka Y, Schneider E, Dy M (October 2000). "Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes". Journal of Immunology. 165 (8): 4367–4371. doi:10.4049/jimmunol.165.8.4367. PMID 11035073.

Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S (October 1996). "Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells". Journal of Immunology. 157 (7): 2909–2915. doi:10.4049/jimmunol.157.7.2909. PMID 8816396.

Guller S, LaChapelle L (March 1999). "The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces". Seminars in Reproductive Endocrinology. 17 (1): 39–44. doi:10.1055/s-2007-1016210. PMID 10406074.

Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N (2014). "Mechanism of activation-induced cell death of T cells and regulation of FasL expression". Critical Reviews in Immunology. 34 (4): 301–314. doi:10.1615/CritRevImmunol.2014009988. PMID 24941158.

Lynch DH, Ramsdell F, Alderson MR (December 1995). "Fas and FasL in the homeostatic regulation of immune responses". Immunology Today. 16 (12): 569–574. doi:10.1016/0167-5699(95)80079-4. PMID 8579749.

Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD, et al. (March 2000). "Sequential involvement of NFAT and Egr transcription factors in FasL regulation". Immunity. 12 (3): 293–300. doi:10.1016/S1074-7613(00)80182-X. PMID 10755616.

Dolicka D, Sobolewski C, Correia de Sousa M, Gjorgjieva M, Foti M (September 2020). "mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer". International Journal of Molecular Sciences. 21 (18): 6648. doi:10.3390/ijms21186648. PMC 7554771. PMID 32932781.

Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S, et al. (July 2002). "c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis". The EMBO Journal. 21 (14): 3704–3714. doi:10.1093/emboj/cdf356. PMC 125398. PMID 12110583.

Wertz IE, Dixit VM (January 2010). "Regulation of death receptor signaling by the ubiquitin system". Cell Death and Differentiation. 17 (1): 14–24. doi:10.1038/cdd.2009.168. PMID 19893571.

Seyrek K, Espe J, Reiss E, Lavrik IN (November 2024). "The Crosstalk of Apoptotic and Non-Apoptotic Signaling in CD95 System". Cells. 13 (21): 1814. doi:10.3390/cells13211814. PMC 11545656. PMID 39513921.

Tummers B, Green DR (May 2017). "Caspase-8: regulating life and death". Immunological Reviews. 277 (1): 76–89. doi:10.1111/imr.12541. PMC 5417704. PMID 28462525.

Wajant H, Pfizenmaier K, Scheurich P (February 2003). "Non-apoptotic Fas signaling". Cytokine & Growth Factor Reviews. 14 (1): 53–66. doi:10.1016/S1359-6101(02)00072-2. PMID 12485619.

Gajate C, Mollinedo F (March 2005). "Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy". The Journal of Biological Chemistry. 280 (12): 11641–11647. doi:10.1074/jbc.M411781200. PMID 15659383.

Micheau O, Tschopp J (July 2003). "Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes". Cell. 114 (2): 181–190. doi:10.1016/s0092-8674(03)00521-x. PMID 12887920. S2CID 17145731.

Parlato S, Giammarioli AM, Logozzi M, Lozupone F, Matarrese P, Luciani F, et al. (October 2000). "CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway". The EMBO Journal. 19 (19): 5123–5134. doi:10.1093/emboj/19.19.5123. PMC 302100. PMID 11013215.

Ghadimi MP, Sanzenbacher R, Thiede B, Wenzel J, Jing Q, Plomann M, et al. (May 2002). "Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178)". FEBS Letters. 519 (1–3): 50–58. doi:10.1016/s0014-5793(02)02709-6. PMID 12023017. S2CID 26765451.

Wenzel J, Sanzenbacher R, Ghadimi M, Lewitzky M, Zhou Q, Kaplan DR, et al. (December 2001). "Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor". FEBS Letters. 509 (2): 255–262. doi:10.1016/s0014-5793(01)03174-x. PMID 11741599. S2CID 33084576.

Hane M, Lowin B, Peitsch M, Becker K, Tschopp J (October 1995). "Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain". FEBS Letters. 373 (3): 265–268. Bibcode:1995FEBSL.373..265H. doi:10.1016/0014-5793(95)01051-f. PMID 7589480. S2CID 24130275.

Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA (April 1997). "Identification of amino acid residues important for ligand binding to Fas". The Journal of Experimental Medicine. 185 (8): 1487–1492. doi:10.1084/jem.185.8.1487. PMC 2196280. PMID 9126929.

Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, et al. (July 1997). "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction". The Journal of Biological Chemistry. 272 (30): 18827–18833. doi:10.1074/jbc.272.30.18827. PMID 9228058.

Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS (May 1999). "A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis". The Journal of Biological Chemistry. 274 (20): 13733–13736. doi:10.1074/jbc.274.20.13733. PMID 10318773.

Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, et al. (May 2002). "Modulation of dendritic cell differentiation and maturation by decoy receptor 3". Journal of Immunology. 168 (10): 4846–4853. doi:10.4049/jimmunol.168.10.4846. PMID 11994433.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. (December 1998). "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer". Nature. 396 (6712): 699–703. Bibcode:1998Natur.396..699P. doi:10.1038/25387. PMID 9872321. S2CID 4427455.

Matson DR, Yang DT (February 2020). "Autoimmune Lymphoproliferative Syndrome: An Overview". Archives of Pathology & Laboratory Medicine. 144 (2): 245–251. doi:10.5858/arpa.2018-0190-RS. PMC 10415410. PMID 30958694.

Strasser A, Jost PJ, Nagata S (February 2009). "The many roles of FAS receptor signaling in the immune system". Immunity. 30 (2): 180–192. doi:10.1016/j.immuni.2009.01.001. PMC 2956119. PMID 19239902.

Restifo NP (May 2000). "Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape". Nature Medicine. 6 (5): 493–495. doi:10.1038/74955. PMC 1955754. PMID 10802692.

Whiteside TL, Rabinowich H (June 1998). "The role of Fas/FasL in immunosuppression induced by human tumors". Cancer Immunology, Immunotherapy. 46 (4): 175–184. doi:10.1007/s002620050476. PMC 11037378. PMID 9671140.

Strand S, Galle PR (February 1998). "Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications". Molecular Medicine Today. 4 (2): 63–68. doi:10.1016/S1357-4310(97)01191-X. PMID 9547792.

Peter ME, Krammer PH (January 2003). "The CD95(APO-1/Fas) DISC and beyond". Cell Death and Differentiation. 10 (1): 26–35. doi:10.1038/sj.cdd.4401186. PMID 12655293.

Martinez OM, Krams SM (January 1999). "Involvement of Fas-Fas ligand interactions in graft rejection". International Reviews of Immunology. 18 (5–6): 527–546. doi:10.3109/08830189909088497. PMID 10672500.

Takeuchi T, Ueki T, Nishimatsu H, Kajiwara T, Ishida T, Jishage K, et al. (January 1999). "Accelerated rejection of Fas ligand-expressing heart grafts". Journal of Immunology. 162 (1): 518–522. doi:10.4049/jimmunol.162.1.518. PMID 9886428.

nih.gov

pubmed.ncbi.nlm.nih.gov

Levoin N, Jean M, Legembre P (2020). "CD95 Structure, Aggregation and Cell Signaling". Frontiers in Cell and Developmental Biology. 8: 314. doi:10.3389/fcell.2020.00314. PMC 7214685. PMID 32432115.

Guégan JP, Legembre P (March 2018). "Nonapoptotic functions of Fas/CD95 in the immune response". The FEBS Journal. 285 (5): 809–827. doi:10.1111/febs.14292. PMID 29032605.

Wajant H, Pfizenmaier K, Scheurich P (February 2003). "Non-apoptotic Fas signaling". Cytokine & Growth Factor Reviews. 14 (1): 53–66. doi:10.1016/S1359-6101(02)00072-2. PMID 12485619.

Taylor AW (2016-02-08). "Ocular Immune Privilege and Transplantation". Frontiers in Immunology. 7: 37. doi:10.3389/fimmu.2016.00037. PMC 4744940. PMID 26904026.

Sheikh MS, Fornace AJ (August 2000). "Death and decoy receptors and p53-mediated apoptosis". Leukemia. 14 (8): 1509–1513. doi:10.1038/sj.leu.2401865. PMID 10942251. S2CID 12572810.

Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I (January 2001). "Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity". Cancer Research. 61 (2): 577–581. PMID 11212252.

Wertz IE, Dixit VM (January 2010). "Regulation of death receptor signaling by the ubiquitin system". Cell Death and Differentiation. 17 (1): 14–24. doi:10.1038/cdd.2009.168. PMID 19893571.

Tummers B, Green DR (May 2017). "Caspase-8: regulating life and death". Immunological Reviews. 277 (1): 76–89. doi:10.1111/imr.12541. PMC 5417704. PMID 28462525.

Wajant H, Pfizenmaier K, Scheurich P (February 2003). "Non-apoptotic Fas signaling". Cytokine & Growth Factor Reviews. 14 (1): 53–66. doi:10.1016/S1359-6101(02)00072-2. PMID 12485619.

Restifo NP (May 2000). "Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape". Nature Medicine. 6 (5): 493–495. doi:10.1038/74955. PMC 1955754. PMID 10802692.

Peter ME, Krammer PH (January 2003). "The CD95(APO-1/Fas) DISC and beyond". Cell Death and Differentiation. 10 (1): 26–35. doi:10.1038/sj.cdd.4401186. PMID 12655293.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Sheikh MS, Fornace AJ (August 2000). "Death and decoy receptors and p53-mediated apoptosis". Leukemia. 14 (8): 1509–1513. doi:10.1038/sj.leu.2401865. PMID 10942251. S2CID 12572810.

Fas ligand (English Wikipedia)

aacrjournals.org

doi.org

elsevier.com

linkinghub.elsevier.com

ensembl.org

May2017.archive.ensembl.org

harvard.edu

ui.adsabs.harvard.edu

nbn-resolving.de

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org